NS5B polymerase inhibitor (sofosbuvir)
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:NS5B_polymerase_inhibitor
antiviral drug |
| gptkbp:activeIngredient |
gptkb:sofosbuvir
|
| gptkbp:approvedBy |
gptkb:FDA
2013 |
| gptkbp:ATCCode |
gptkb:J05AX15
|
| gptkbp:brand |
gptkb:Sovaldi
|
| gptkbp:CASNumber |
1190307-88-0
|
| gptkbp:combines |
gptkb:daclatasvir
ledipasvir velpatasvir |
| gptkbp:discoveredBy |
gptkb:Gilead_Sciences
|
| gptkbp:eliminationHalfLife |
0.4 hours (sofosbuvir), 27 hours (GS-331007 metabolite)
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C22H29FN3O9P
|
| https://www.w3.org/2000/01/rdf-schema#label |
NS5B polymerase inhibitor (sofosbuvir)
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HCV NS5B RNA-dependent RNA polymerase
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B1 (Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache insomnia |
| gptkbp:usedFor |
treatment of hepatitis C
|
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:Harvoni
|
| gptkbp:bfsLayer |
6
|